Enhanced Chemo‐Immunotherapy Strategy Utilizing Injectable Thermosensitive Hydrogel for The Treatment of Diffuse Peritoneal Metastasis in Advanced Colorectal Cancer
Meng Wang,DanRong Hu,Yun Yang,Kun Shi,JiaNan Li,QingYa Liu,YiCong Li,Ran Li,Meng Pan,Dong Mo,Wen Chen,XiCheng Li,ZhiYong Qian
DOI: https://doi.org/10.1002/advs.202303819
IF: 15.1
2023-10-26
Advanced Science
Abstract:Patients with colorectal cancer (CRC) and diffuse peritoneal metastasis (PM) are not eligible for surgery. A customized OxP/R848@PLEL hydrogel delivery system has been developed. The PLEL hydrogel forms a drug depot within the abdominal cavity. OxP can enhance the immunogenicity of tumors. OxP/R848 exhibits a "tumor vaccine‐like" effect that elicits specific immunity. OxP/R848@PLEL effectively eradicates PM and significantly prolongs mice lifespan. Patients with colorectal cancer (CRC) and diffuse peritoneal metastasis (PM) are not eligible for surgical intervention. Thus, palliative treatment remains the standard of care in clinical practice. Systemic chemotherapy fails to cause drug accumulation at the lesion sites, while intraperitoneal chemotherapy (IPC) is limited by high clearance rates and associated complications. Given the poor prognosis, a customized OxP/R848@PLEL hydrogel delivery system has been devised to improve the clinical benefit of advanced CRC with diffuse PM. This system is distinguished by its simplicity, security, and efficiency. Specifically, the PLEL hydrogel exhibits excellent injectability and thermosensitivity, enabling the formation of drug depots within the abdominal cavity, rendering it an optimal carrier for IPC. Oxaliplatin (OxP), a first‐line drug for advanced CRC, is cytotoxic and enhances the immunogenicity of tumors by inducing immunogenic cell death. Furthermore, OxP and resiquimod (R848) synergistically enhance the maturation of dendritic cells, promote the expansion of cytotoxic T lymphocytes, and induce the formation of central memory T cells. Moreover, R848 domesticates macrophages to an anti‐tumor phenotype. OxP/R848@PLEL effectively eradicates peritoneal metastases, completely inhibits ascites production, and significantly prolongs mice lifespan. As such, it provides a promising approach to managing diffuse PM in patients with CRC without surgical indications.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry